The United States Patent and Trademark Office (USPTO) has issued Patent No. US 9,956,211 which protects BUPI, currently in development for pain due to oral mucositis.
This patent should provide protection through to 2032.
The U.S. patent covers a method for the treatment of pain due to oral mucositis in cancer patients by locally administering a sustained-release lozenge in which the local anesthetic bupivacaine is the active ingredient. Moberg Pharma has previously announced patent grants in Europe and Canada.
“This issuance of this patent in the United States is part of our overall strategy to establish a broad portfolio of patent claims to protect our proprietary products and is an important milestone, as we now have granted patents in all territories where we have applied for patent protection.”commented Peter Wolpert, Moberg Pharma’s CEO.
In 2016, Moberg Pharma announced positive Phase 2 results with BUPI in treating pain associated with oral mucositis in patients with head and neck cancer undergoing radiotherapy. Moberg Pharma estimates that the product has a sales potential amounting to USD 100–200 million annually, assuming successful commercialization in oral mucositis and at least one further indication.